Impacts of anti-EGFR monoclonal antibody in prostate cancer PC3 cells

Human Antibodies

Volumn 19, Issue 2-3, 2010, Pages 63-70

  Rezaiemanesh, Alireza ^a,b   Majidi, Jafar ^b,c   Baradaran, Behzad ^b,c   Movasaghpour, Aliakbar ^b   Nakhlband, Ailar ^a   Barar, Jaleh ^a,c   Omidi, Yadollah ^a,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Epidermal growth factor receptor; Monoclonal antibody; PC3 cell line; Prostate cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCLONAL ANTIBODY; PROTEIN KINASE B; STAT5 PROTEIN;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DOSE TIME EFFECT RELATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FLOW CYTOMETRY; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77957285819     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2010-0229     Document Type: Article

References (34)

1. S. DoyleLindrud, Prostate Cancer: A Chronic Illness, Clinical Journal of Oncology Nursing 11 (2007), 857-861.
2. J.Majidi, J. Barar, B. Baradaran, J.Abdolalizadeh andY.Omidi, Target therapy of cancer: implementation of monoclonal antibodies and Nanobodies, Human Antibodies 18 (2009), 81-100.
3. J. Barton, G. Blackledge and A. Wakeling, Growth factors and their receptors: new targets for prostate cancer therapy, Urology 58 (2001), 114-122. (Pubitemid 32743426)
4. B.J. Feldman and D. Feldman, The development of androgenindependent prostate cancer, Nat Rev Cancer 1 (2001), 34-45.
5. M. Mimeault and S.K. Batra, Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies, Carcinogenesis 27 (2006), 1-22. (Pubitemid 43032978)
6. J. Mendelsohn and J. Baselga, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer, J Clin Oncol 21 (2003), 2787-2799. (Pubitemid 46606324)
7. S. Agelaki, M. Spiliotaki, H. Markomanolaki, G. Kallergi, D. Mavroudis, V. Georgoulias et al., Caveolin1 regulates EGFR signalling inMCF7 breast cancer cells and enhances gefitinibinduced tumor cell inhibition, Cancer Biol Ther 8 (2009).
8. K.C. Jordan, S.D. Hatfield, M. Tworoger, E.J.Ward, K.A. Fischer, S. Bowers et al., Genome wide analysis of transcript levels after perturbation of the EGFR pathway in the Drosophila ovary, Dev Dyn 232 (2005), 709-724. (Pubitemid 40315290)
9. G.P.Amorino, P.D.Deeble and S.J. Parsons, Neurotensin stimulates mitogenesis of prostate cancer cells through a novel cSrc/Stat5b pathway, Oncogene 26 (2007), 745-756.
10. R. Alonzi and P. Hoskin, Novel therapies in bladder cancer, Clin Oncol (R Coll Radiol) 17 (2005), 524-538. (Pubitemid 41350120)
11. S. Hosokawa, S. Toyooka, Y. Fujiwara, M. Tokumo, J. Soh, N. Takigawa et al., Comprehensive analysis of EGFR signaling pathways in Japanese patients with nonsmall cell lung cancer, Lung Cancer 66 (2009), 107-113.
12. C. Athale, Y.Mansury and T.S. Deisboeck, Simulating the impact of a 'molecular decision' process on cellular phenotype and multicellular patterns in brain tumors, J Theor Biol 233 (2005), 469-481. (Pubitemid 40320594)
13. H.I. Scher, A. Sarkis, V. Reuter, D. Cohen, G. Netto, D. Petrylak et al., Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms, Clinical Cancer Research 1 (1995), 545-550.
14. N. Normanno, L.A. De, C. Bianco, L. Strizzi, M. Mancino, M.R.Maiello et al., Epidermal growth factor receptor (EGFR) signaling in cancer, Gene 366 (2006), 2-16. (Pubitemid 43199589)
15. C. Mamot and C. Rochlitz, Targeting the epidermal growth factor receptor (EGFR) - a new therapeutic option in oncology?, Swiss Med Wkly 136 (2006), 4-12. (Pubitemid 43151760)
16. F. Afaq, N. Zaman, N. Khan, D.N. Syed, S. Sarfaraz, M.A. Zaid et al., Inhibition of epidermal growth factor receptor signaling pathway by delphinidin, an anthocyanidin in pigmented fruits and vegetables, Int J Cancer 123 (2008), 1508-1515.
17. E.R. Camp, J. Summy, T.W. Bauer, W. Liu, G.E. Gallick and L.M. Ellis, Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor, Clin Cancer Res 11 (2005), 397-405. (Pubitemid 40075820)
18. S. Loew, U. Schmidt, A. Unterberg and M.E. Halatsch, The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms, Anticancer Agents Med Chem 9 (2009), 703-715. (Pubitemid 43362229)
19. C. Gialeli, D. Kletsas, D. Mavroudis, H.P. Kalofonos, G.N. Tzanakakis and N.K. Karamanos, Targeting epidermal growth factor receptor in solid tumors: Critical evaluation of the biological importance of therapeutic monoclonal antibodies, Current Medicinal Chemistry 16 (2009), 3797-3804.
20. B. Baradaran, A. Zavaran Hosseini, J. Majidi, S. Farajnia, J. Barar, Z.M. Hassan et al., Development and characterization of monoclonal antibodies against human epidermal growth factor receptor in Balb/c mice, Human Antibodies 18 (2009), in press.
21. M.Watanabe, T. Nakada and H. Yuta, Analysis of Protooncogene cerbB2 in Benign and Malignant Human Prostate, International Urology and Nephrology 31 (1999), 61-73. (Pubitemid 29284490)
22. P.M. Harari, Epidermal growth factor receptor inhibition strategies in oncology, Endocr Relat Cancer 11 (2004), 689-708. (Pubitemid 40065545)
23. S.S. El Sheikh, J. Domin, P. Abel, G. Stamp and E. Lalani, Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF, Neoplasia 6 (2004), 846-853. (Pubitemid 40041504)
24. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang and C.G. Davis, Development of ABXEGF, a fully human antiEGF receptor monoclonal antibody, for cancer therapy, Crit Rev Oncol Hematol 38 (2001), 17-23. (Pubitemid 32194591)
25. J. Mendelsohn and J. Baselga, Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer, J Clin Oncol 21 (2003), 2787-2799. (Pubitemid 46606324)
26. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang and C.G. Davis, Development of ABXEGF, a fully human antiEGF receptor monoclonal antibody, for cancer therapy, Crit Rev Oncol Hematol 38 (2001), 17-23. (Pubitemid 32194591)
27. Y.F. Yu, Z.W. Chen, Z.M. Li, Z.H. Li and S. Lu, The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin8 expression in human lung adenocarcinoma cells, Current Therapeutic Research 70 (2009), 116-128.
28. J.Mendelsohn, Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy, Clinical Cancer Research 3 (1997), 2703-2707. (Pubitemid 28133130)
29. D. Raben, B. Helfrich, D.C. Chan, F. Ciardiello, L. Zhao, W. Franklin et al., The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer, Clinical Cancer Research 11 (2005), 795805. (Pubitemid 40116908)
30. S. Oliveira, P.M. van Bergen en Henegouwen, G. Storm and R.M. Schiffelers, Molecular biology of epidermal growth factor receptor inhibition for cancer therapy, Expert Opin Biol Ther 6 (2006), 605-617. (Pubitemid 43837187)
31. J. Baselga, The EGFR as a target for anticancer therapy-focus on cetuximab, Eur J Cancer 37(Suppl 4) (2001), S16-S22. (Pubitemid 32938125)
32. B.F. ElRayes and P.M. LoRusso, Targeting the Epidermal Growth Factor Receptor, Br J Cancer 91 (2004), 418-424. (Pubitemid 39093557)
33. R. Bianco, T. Troiani, G. Tortora and F. Ciardiello, Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy, Endocr Relat Cancer 12 (2005), S159-S171. (Pubitemid 41395423)
34. F. Cappuzzo, E.Magrini, G.L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini et al., Akt phosphorylation and gefitinib efficacy in patients with advanced nonsmallcell lung cancer, J Natl Cancer Inst 96 (2004), 1133-1141. (Pubitemid 39207049)